Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06743022

Evaluation of the Reproducibility of the Automated Measurement of the Extent of ILD on Chest CT

In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. Automated tools are now available to quantify ILD, but there is a lack of data on the reproducibility of this measurement and therefore its accuracy.

Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT. Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

APHP - Bichat Hospital - Pneumology, Paris, IDF, France

Loading trial locations.

About this study

In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. In recent years, several tools based on texture analysis or deep learning methods have been developed to provide rapid and accurate automated quantification of ILD extent.

An advantage of automated scoring methods is that they theoretically offer perfect repeatability of measurement. However, this is only true if the measurement is repeated on the same images. Several parameters can alter the appearance of the lungs on scanner images, such as the degree of inspiration or the reconstruction kernel used to reconstruct the images. There is a lack of data on the reproducibility of the whole process of automated ILD quantification and therefore its accuracy.

Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT.

Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease in patients with ILD from 2 institutions. Chest CT will be repeated the same day. This will allow assessment of the variability of automated measurement of ILD extent between 2 CT scans performed on the same day and when using different software. It will also allow to assess the variability of lung volume between the 2 CT scans and the effect of disease (idiopathic pulmonary fibrosis or connective tissue disease-related ILD) on the reproducibility of ILD quantification.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Known interstitial lung disease as part of idiopathic pulmonary fibrosis or connective tissue disease
  • Followed in one of the participating hospitals
  • Requiring a chest CT as part of a scheduled assessment
  • Affiliated to a French national social security
  • Informed consent

Exclusion criteria

  • Acute exacerbation of ILD
  • Pregnancy
  • Inability to hold an apnea for 10 seconds
  • Patients in the exclusion period after a previous research
  • Need for additional procubitus or expiratory images

Treatment and study plan

Chest CT

Diagnostic Test

Repeated chest CT for automated ILD quantification

Primary outcomes

  1. Automated Interstitial Lung Disease (ILD) quantification

    Time frame: Day of inclusion

    Reproducibility of ILD quantification on chest CT (as a percentage of lung volume) between two successive scan acquisitions.

Secondary outcomes

  1. Automated Interstitial Lung Disease (ILD) quantification

    Time frame: Day of inclusion

    Reproducibility of disease extent measured with different software on the same acquisition

  2. Lung volume

    Time frame: Day of inclusion

    Reproducibility of total lung volume measured on the scanner between two successive acquisitions

  3. Automated Interstitial Lung Disease (ILD) quantification

    Time frame: Day of inclusion

    Reproducibility of disease extension between the two scan acquisitions depending on the disease (idiopathic pulmonary fibrosis or PID secondary to connective tissue disease).

Study contacts

Contact information is provided by the study sponsor or research team.

Guillaume CHASSAGNON, MD, PhD

CONTACT

[email protected]

+33158414326

Marie BENHAMMANI-GODARD

CONTACT

[email protected]

0033158411190

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Evaluation of the Reproducibility of the Automated Measurement of the Extent of Interstitial Lung Disease on Chest CT

Acronym: REPRO-PID

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 19, 2024
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.